Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.

The metacestode stage of Echinococcus granulosus can cause cystic echinococcosis (CE), which still widely occurs around the world. Since the early 1970s, benzimidazoles have been shown to inhibit the growth of cysts and used to treat CE. However, benzimidazoles are still ineffective in 20%-40% of ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan Zhang, Jianghua Wang, Qingxia Yang, Zhi Li, Xiaoying Xu, Chong Chen, Zongjie Hou, Qi He, Li Sheng, Xingming Ma, Yanping Luo
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/830e87902e9d401f96f9714a86fd8a06
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:830e87902e9d401f96f9714a86fd8a06
record_format	dspace
spelling	oai:doaj.org-article:830e87902e9d401f96f9714a86fd8a062021-12-02T20:24:14ZSynergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.1935-27271935-273510.1371/journal.pntd.0009927https://doaj.org/article/830e87902e9d401f96f9714a86fd8a062021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pntd.0009927https://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735The metacestode stage of Echinococcus granulosus can cause cystic echinococcosis (CE), which still widely occurs around the world. Since the early 1970s, benzimidazoles have been shown to inhibit the growth of cysts and used to treat CE. However, benzimidazoles are still ineffective in 20%-40% of cases. In order to explore the new agents against CE, we have investigated the therapeutic effect of the recombinant adenoviral vector expressing mouse IL-28B (rAd-mIL-28B) on protoscoleces-infected mice. In our study, we successfully established the model mice which infected with protoscoleces intraperitoneally. At 18 weeks post-infection, the mice received rAd-mIL-28B (1×107 PFU) weekly by intramuscular injection for 6 weeks. Compared with the untreated control (13.1 ± 2.2 g), there was a significant reduction in cysts wet weight in rAd-mIL-28B group (8.3 ± 3.5 g) (P < 0.05), especially in Albendazole (ABZ) + rAd-mIL-28B group (5.8 ± 1.4 g) (P < 0.01). We also observed the severe damage of the germinal layer and the laminated layer of cysts after treatment. rAd-mIL-28B group showed a prominent increase in the level of Th1 type cytokines (such as IFN-γ, IL-2 and TNF-α). Meanwhile, the frequency of Foxp3+ T cells was decreased in the rAd-mIL-28B group (4.83 ± 0.81%) and ABZ + rAd-mIL-28B group (4.60 ± 0.51%), comparing with the untreated group (8.13 ± 2.60%) (P < 0.05). In addition, compared with the untreated control (122.14 ± 81.09 pg/ml), the level of IFN-γ significantly increased in peritoneal fluid in the rAd-mIL-28B group (628.87 ± 467.16 pg/ml) (P < 0.05) and ABZ + rAd-mIL-28B group (999.76 ± 587.60 pg/ml) (P < 0.001). Taken together, it suggested that ABZ + IL-28B may be a potential therapeutic agent against CE.Yan ZhangJianghua WangQingxia YangZhi LiXiaoying XuChong ChenZongjie HouQi HeLi ShengXingming MaYanping LuoPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 15, Iss 11, p e0009927 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Yan Zhang Jianghua Wang Qingxia Yang Zhi Li Xiaoying Xu Chong Chen Zongjie Hou Qi He Li Sheng Xingming Ma Yanping Luo Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
description	The metacestode stage of Echinococcus granulosus can cause cystic echinococcosis (CE), which still widely occurs around the world. Since the early 1970s, benzimidazoles have been shown to inhibit the growth of cysts and used to treat CE. However, benzimidazoles are still ineffective in 20%-40% of cases. In order to explore the new agents against CE, we have investigated the therapeutic effect of the recombinant adenoviral vector expressing mouse IL-28B (rAd-mIL-28B) on protoscoleces-infected mice. In our study, we successfully established the model mice which infected with protoscoleces intraperitoneally. At 18 weeks post-infection, the mice received rAd-mIL-28B (1×107 PFU) weekly by intramuscular injection for 6 weeks. Compared with the untreated control (13.1 ± 2.2 g), there was a significant reduction in cysts wet weight in rAd-mIL-28B group (8.3 ± 3.5 g) (P < 0.05), especially in Albendazole (ABZ) + rAd-mIL-28B group (5.8 ± 1.4 g) (P < 0.01). We also observed the severe damage of the germinal layer and the laminated layer of cysts after treatment. rAd-mIL-28B group showed a prominent increase in the level of Th1 type cytokines (such as IFN-γ, IL-2 and TNF-α). Meanwhile, the frequency of Foxp3+ T cells was decreased in the rAd-mIL-28B group (4.83 ± 0.81%) and ABZ + rAd-mIL-28B group (4.60 ± 0.51%), comparing with the untreated group (8.13 ± 2.60%) (P < 0.05). In addition, compared with the untreated control (122.14 ± 81.09 pg/ml), the level of IFN-γ significantly increased in peritoneal fluid in the rAd-mIL-28B group (628.87 ± 467.16 pg/ml) (P < 0.05) and ABZ + rAd-mIL-28B group (999.76 ± 587.60 pg/ml) (P < 0.001). Taken together, it suggested that ABZ + IL-28B may be a potential therapeutic agent against CE.
format	article
author	Yan Zhang Jianghua Wang Qingxia Yang Zhi Li Xiaoying Xu Chong Chen Zongjie Hou Qi He Li Sheng Xingming Ma Yanping Luo
author_facet	Yan Zhang Jianghua Wang Qingxia Yang Zhi Li Xiaoying Xu Chong Chen Zongjie Hou Qi He Li Sheng Xingming Ma Yanping Luo
author_sort	Yan Zhang
title	Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
title_short	Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
title_full	Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
title_fullStr	Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
title_full_unstemmed	Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.
title_sort	synergism therapeutic and immunoregulatory effects of albendazole + rad-mil-28b against echinococcosis in experiment-infected mice with protoscoleces.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/830e87902e9d401f96f9714a86fd8a06
work_keys_str_mv	AT yanzhang synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT jianghuawang synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT qingxiayang synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT zhili synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT xiaoyingxu synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT chongchen synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT zongjiehou synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT qihe synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT lisheng synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT xingmingma synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces AT yanpingluo synergismtherapeuticandimmunoregulatoryeffectsofalbendazoleradmil28bagainstechinococcosisinexperimentinfectedmicewithprotoscoleces
_version_	1718374059634327552

Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.

Ejemplares similares